Zydus Lifesciences Q3 FY24 PAT up 26.8%

Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.

Qure.ai adds new FDA breakthrough device status for qSpot-TB

4 FDA clearances & 61 EU MDR CE tags achieved for AI in 18 months

WACKER to exhibit new adhesive, medical solutions at MD&M West

Sun Pharma Advanced Research Company Q3 FY24 loss at Rs. 99.65 Cr

Sun Pharma Advanced Research Company has reported total income of Rs. 20.25 crores during the period ended December 31, 2023

RPG Life Sciences posts Q3 FY24 PAT at Rs. 26.46 Cr

RPG Life Sciences Limited has reported total income of Rs. 155.62 crores during the period ended December 31, 2023

TTK Healthcare posts Q3 FY24 PAT at Rs. 12.89 Cr

TTK Healthcare has reported total income of Rs. 199.75 crores during the period ended December 31, 2023

Abbott India posts Q3 FY24 PAT at Rs. 310.98 Cr

Abbott India has reported total income of Rs. 1492.75 crores during the period ended December 31, 2023

Industry’s reaction to Union Budget 2024-25

Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry

Glenmark partners Pfizer to launch Abrocitinib in India

Developed by Pfizer, Abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India

Orchid Pharma's Exblifeb granted EMA approval

Exblifeb demonstrates remarkable efficacy in treating complicated Urinary Tract Infections (cUTI), pneumonia